Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America
Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic partnership with HealingMaps and Advanced Behavioral Strategies to provide EEG-based cognitive analytics to over 2,500 specialized clinics across North America. The collaboration follows HealingMaps' launch of the Healing Health Alliance, a pioneering Group Purchasing Organization for alternative therapy clinics.
The partnership will integrate Firefly's FDA-510(k)-cleared brain health analytics platform, which uses AI and EEG technology to provide objective assessments, replacing traditional subjective questionnaires. The platform analyzes brain activity using the world's largest normative EEG/ERP database, offering standardized insights for ketamine, psilocybin, and TMS treatments.
Firefly Neuroscience (NASDAQ: AIFF) ha annunciato una partnership strategica con HealingMaps e Advanced Behavioral Strategies per fornire analisi cognitive basate su EEG a oltre 2.500 cliniche specializzate in Nord America. La collaborazione segue il lancio da parte di HealingMaps della Healing Health Alliance, una pionieristica organizzazione per acquisti aggregati rivolta alle cliniche di terapie alternative.
La partnership integrerà la piattaforma di analisi della salute cerebrale di Firefly, approvata FDA-510(k), che sfrutta IA e tecnologia EEG per offrire valutazioni oggettive in sostituzione dei tradizionali questionari soggettivi. La piattaforma analizza l'attività cerebrale utilizzando il più grande database normativo mondiale di EEG/ERP, fornendo informazioni standardizzate per i trattamenti con ketamina, psilocibina e TMS.
Firefly Neuroscience (NASDAQ: AIFF) anunció una alianza estratégica con HealingMaps y Advanced Behavioral Strategies para ofrecer análisis cognitivos basados en EEG a más de 2.500 clínicas especializadas en Norteamérica. La colaboración llega tras el lanzamiento por parte de HealingMaps de la Healing Health Alliance, una innovadora organización de compras colectivas para clínicas de terapias alternativas.
La asociación integrará la plataforma de análisis de salud cerebral de Firefly, con autorización FDA-510(k), que utiliza IA y tecnología EEG para proporcionar evaluaciones objetivas en lugar de los cuestionarios subjetivos tradicionales. La plataforma analiza la actividad cerebral usando la base de datos normativa de EEG/ERP más grande del mundo, ofreciendo perspectivas estandarizadas para tratamientos con ketamina, psilocibina y TMS.
Firefly Neuroscience (NASDAQ: AIFF)는 HealingMaps 및 Advanced Behavioral Strategies와 전략적 제휴를 맺고 북미 전역의 2,500개 이상의 전문 클리닉에 EEG 기반 인지 분석을 제공한다고 발표했습니다. 이번 협력은 대체 치료 클리닉을 위한 선구적인 단체 구매 조직인 Healing Health Alliance를 HealingMaps가 출범한 데 따른 것입니다.
이번 파트너십은 Firefly의 FDA-510(k) 승인 뇌 건강 분석 플랫폼을 통합합니다. 이 플랫폼은 AI와 EEG 기술을 활용해 기존의 주관적 설문을 대체하는 객관적 평가를 제공합니다. 플랫폼은 세계 최대 규모의 규준 EEG/ERP 데이터베이스를 사용해 뇌 활동을 분석하며 케타민, 실로시빈, TMS 치료에 대한 표준화된 인사이트를 제공합니다.
Firefly Neuroscience (NASDAQ: AIFF) a annoncé un partenariat stratégique avec HealingMaps et Advanced Behavioral Strategies afin de fournir des analyses cognitives basées sur l'EEG à plus de 2 500 cliniques spécialisées en Amérique du Nord. Cette collaboration intervient après le lancement par HealingMaps de la Healing Health Alliance, une organisation d'achat groupé innovante pour les cliniques de thérapies alternatives.
Le partenariat intégrera la plateforme d'analyse de la santé cérébrale de Firefly, homologuée FDA-510(k), qui utilise l'IA et la technologie EEG pour fournir des évaluations objectives en remplacement des questionnaires subjectifs traditionnels. La plateforme analyse l'activité cérébrale en s'appuyant sur la plus grande base de données normative EEG/ERP au monde, offrant des insights standardisés pour les traitements par kétamine, psilocybine et TMS.
Firefly Neuroscience (NASDAQ: AIFF) hat eine strategische Partnerschaft mit HealingMaps und Advanced Behavioral Strategies angekündigt, um EEG-basierte kognitive Analysen an mehr als 2.500 spezialisierte Kliniken in Nordamerika zu liefern. Die Zusammenarbeit folgt auf die Gründung der Healing Health Alliance durch HealingMaps, einer wegweisenden Gruppen-Einkaufsorganisation für Kliniken alternativer Therapien.
Die Partnerschaft wird Fireflys FDA-510(k)-zugelassene Plattform zur Analyse der Gehirngesundheit integrieren, die KI und EEG-Technologie nutzt, um objektive Bewertungen statt herkömmlicher subjektiver Fragebögen zu liefern. Die Plattform wertet Gehirnaktivität anhand der weltweit größten normativen EEG/ERP-Datenbank aus und bietet standardisierte Einblicke für Behandlungen mit Ketamin, Psilocybin und TMS.
- None.
- None.
Insights
Firefly's partnership with HealingMaps expands its AI-driven EEG analytics to 2,500+ alternative treatment clinics, creating new revenue opportunities.
Firefly Neuroscience's new partnership with HealingMaps represents a significant market expansion opportunity for the company's FDA-510(k)-cleared brain health analytics platform. By joining forces with North America's leading directory for alternative neurological treatments, Firefly gains access to over 2,500 ketamine, psychedelic-assisted therapy, and TMS clinics across the continent.
This collaboration addresses a critical gap in neurological and mental healthcare. Currently, most clinics rely on subjective assessments or patient-reported questionnaires to guide treatment decisions. Firefly's platform offers these clinics objective, AI-driven analytics based on EEG assessments, leveraging what the company describes as the world's largest normative EEG/ERP data repository.
For Firefly, this partnership creates multiple growth vectors. First, it substantially expands their potential customer base through HealingMaps' extensive network. Second, by integrating with the newly launched Healing Health Alliance Group Purchasing Organization, Firefly positions itself as a preferred vendor with streamlined purchasing channels. This should reduce sales friction and potentially accelerate adoption rates across the network.
For clinics, Firefly's technology offers a compelling value proposition: the ability to demonstrate measurable brain health improvements from their treatments. This objective data can build patient confidence, potentially improving treatment adherence and patient retention while opening new revenue streams for clinics. For a company focused on AI applications in neurological health, securing this distribution channel represents a strategic move to capture market share in the growing alternative neurological treatment sector.
KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a new partnership with HealingMaps, the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (“TMS”) clinics, and Advanced Behavioral Strategies (ABS).
The collaboration comes on the heels of HealingMaps and Capstone Management Group announcing their official launch of the Healing Health Alliance*, the first-of-its-kind Group Purchasing Organization (“GPO”) dedicated to supporting ketamine clinics, psilocybin retreats, TMS clinics, and more. It will provide HealingMaps’ large and growing provider network with one-stop purchasing and preferred pricing for Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain health analytics platform.
Addressing a Critical Gap in Care
Today, most neurological and mental health clinics rely on patient-reported questionnaires or subjective assessments to guide treatment and measure success. Firefly’s platform replaces this with a simple, non-invasive EEG assessment that uses AI to analyze brain activity across multiple regions, comparing patient data against Firefly’s proprietary database - the world’s largest known normative EEG/ERP data repository.
Key Benefits for Clinics
- Objective, FDA-Cleared Analytics: Standardized brain health insights that complement ketamine, psilocybin, and TMS treatment models.
- Demonstrated Outcomes: Providers can show patients measurable brain health changes correlated to treatment.
- Improved Patient Confidence: Objective data builds trust, enhances transparency, and supports long-term care engagement.
“Firefly’s mission is to harness the power of AI and EEG to transform brain health,” said Greg Lipschitz, Chief Executive Officer of Firefly Neuroscience. “By partnering with HealingMaps, we are significantly expanding access to our FDA-cleared brain analytics platform, empowering ketamine, psilocybin, and TMS clinics to strengthen care, prove outcomes, and grow sustainable new revenue streams.”
Cory Jones, Co-Founder of HealingMaps, added, “HealingMaps exists to connect patients with trusted, innovative providers. Partnering with Firefly means our provider network can now access unique, objective brain health analytics that provide evidence-based outcome analyses and potential new revenue opportunities, while giving patients greater confidence in their care.”
About Firefly Neuroscience
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly’s proprietary database currently consists of over 180,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
About HealingMaps
HealingMaps is the leading global directory for finding trusted clinics and practitioners offering psychedelic-assisted therapy, ketamine treatments, TMS, and mental wellness solutions. By connecting individuals with qualified providers, HealingMaps helps make innovative therapies more accessible while empowering clinics with tools, partnerships, and resources to thrive.
* Sign up for the Healing Health Alliance GPO here. There is no obligation or cost to be a member.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
FAQ
What is the partnership between Firefly Neuroscience (AIFF) and HealingMaps?
How does Firefly's (AIFF) brain health analytics platform work?
What are the benefits for clinics using Firefly's (AIFF) platform?
How does Firefly's (AIFF) platform improve upon current treatment assessment methods?
What is the Healing Health Alliance mentioned in the Firefly (AIFF) partnership?
